Mural Oncology (MURA) Revenue & Revenue Breakdown
Mural Oncology Revenue Highlights
00
Mural Oncology Revenue by Period
Mural Oncology Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | - |
Mural Oncology generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Mural Oncology Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $3.49M | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.62M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | - |
Mural Oncology generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Mural Oncology Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| GBIO | Generation Bio | $19.89M | $765.00K |
| VERU | Veru | $16.89M | - |
| VRCA | Verrica Pharmaceuticals | $7.57M | $14.34M |
| BTAI | BioXcel Therapeutics | $2.27M | $120.00K |
| SABS | SAB Biotherapeutics | $2.24M | - |
| EVAX | Evaxion Biotech | $73.11K | $50.88K |
| BCAB | BioAtla | - | - |
| LIMN | Liminatus Pharma, Inc. Class A | - | - |
| ATHE | Alterity Therapeutics | - | $812.12K |
| MURA | Mural Oncology | - | - |
| JSPR | Jasper Therapeutics | - | - |